Bendectin and birth defects : the challenges of mass toxic substances litigation /

Mostrar otras versiones (1)

Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabi...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Green, Michael D., 1950-
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Philadelphia : University of Pennsylvania Press, ©1996.
Temas:
Products liability > Drugs > United States.
Toxic torts > United States.
Complex litigation > United States.
Bendectin (Trademark) > Toxicology.
Abnormalities, Human.
Abnormalities, Drug-Induced > legislation & jurisprudence
Consumer Product Safety > legislation & jurisprudence
Doxylamine > adverse effects
Doxylamine > legislation & jurisprudence
Pyridoxine > adverse effects
Pyridoxine > legislation & jurisprudence
Responsabilité du fait des produits > Médicaments > États-Unis.
Responsabilité pour dommages causés par les substances dangereuses > États-Unis.
Instances complexes > États-Unis.
LAW > Administrative Law & Regulatory Practice.
LAW > Civil Procedure.
LAW > Legal Services.
POLITICAL SCIENCE > Government > Judicial Branch.
Abnormalities, Human
Bendectin (Trademark) > Toxicology
Complex litigation
Products liability > Drugs
Toxic torts
United States
Acceso en línea:Texto completo

Internet

Texto completo

Error inesperado del formato de respuesta.
Detalle de Existencias desde

Ejemplares similares